In HER-2 positive and HR positive tumor xenotransplantation mice, after the treatment of paclitaxel combined with trastuzumab ± pertuzumab, the mice treated with single drug fulvestrant relapsed rapidly, while the mice treated with neratinib plus fulvestrant maintained a longer time of tumor remission(Sudhan et al. 2019). The gene discussed is ERBB2; the disease is neoplasm.